Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : SNYNF save search
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial asses...
Published: 2022-07-14 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results sanofi phase 3
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 1.04%
H: 1.53%
C: 1.37%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: -3.53%
H: 0.0%
C: -1.2%
results phase 3
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
Published: 2022-05-21 (Crawled : 12:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
evkeeza children cholesterol trial phase 3 rare
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
Published: 2022-04-29 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
NVO | $122.75 -1.43% 0.67% 42K
|
Health Technology
|
| O: 5.98%
H: 1.44%
C: -0.42%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
IPHA | $2.35 -2.49% -0.42% 0
|
Health Technology
|
| O: 11.11%
H: 3.67%
C: -4.33%
AZN | $68.36 -0.25% -0.25% 27K
|
Health Technology
|
| O: 0.53%
H: 2.37%
C: 0.26%
trial payment cancer phase 3
Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
dupixent phase 3
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Published: 2022-03-26 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
dupixent phase 3
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
Published: 2022-03-03 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -6.92%
H: 1.86%
C: 1.86%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
trial disease phase 3
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Published: 2022-02-26 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
dupixent urticaria phase 3 hiv
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Published: 2022-02-18 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Published: 2022-02-18 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Published: 2022-01-19 (Crawled : 07:00) - globenewswire.com
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
|
| O: 1.84%
H: 1.79%
C: 0.18%
dupixent trial positive phase 3
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
Published: 2021-12-15 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.76%
H: 2.5%
C: 2.5%
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: 0.0%
covid-19 trial covid positive vaccine phase 3
Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions
Published: 2021-12-14 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -0.56%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
phase 3
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
dupixent atopic dermatitis dermatitis positive children phase 3
New Results from ATLAS Phase 3 Program with Fitusiran Presented at ASH Annual Meeting 2021
Published: 2021-12-12 (Crawled : 20:20) - alnylam.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: 2.8%
H: 0.0%
C: 0.0%
results phase 3
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
Published: 2021-12-08 (Crawled : 23:00) - globenewswire.com
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
|
| O: -0.62%
H: 2.7%
C: 2.42%
dupixent positive results children phase 3
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Published: 2021-11-22 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: -1.72%
H: 1.02%
C: 0.49%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
BNTX | $86.17 -0.27% -0.24% 2.2K
|
Health Technology
|
| O: 7.04%
H: 8.12%
C: 7.96%
covid vaccine phase 3 trial
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
GLAXF | $20.2 0.65% -14.18% 0
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -0.31%
GSK | $39.27 -0.83% 0.38% 3.8K
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
VIR | $7.96 -3.52% -3.64% 0
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
covid treatment phase 3 trial
New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Published: 2021-11-08 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 0
|
Health Technology
|
| O: 3.88%
H: 0.78%
C: 0.68%
covid casirivimab phase 3
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
XPON | News | $3.15 63.21% 33.9% 100K
|
EGOX | $0.036 12.15% 31.56% 32M
|
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
TPET | $0.3279 -3.56% 23.57% 11M
|
n/a
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.